Electrotherapy Companies

Top Industry Leaders in the Electrotherapy Market

*Disclaimer: List of key companies in no particular orderLatest Electrotherapy Companies Update

August 2023: Longbio Pharma (Suzhou) has announced positive results from a Phase I clinical trial of LP-003, a novel long-acting anti-IgE antibody for the treatment of allergic rhinitis. In a randomized, double-blind study, the pharmacokinetics, pharmacodynamics (free IgE levels), and safety of LP-003 in healthy subjects were evaluated. The subjects were randomized into five groups and administered a single intravenous dose of 0, 1, 3, 6, and 10 mg/kg, respectively. Patients exhibited a non-linear PK characteristic with a T1/2 ranging from 46,3 days to 75,6 days, which is approximately 23 times that of omalizumab. LP-003 also exhibited high IgE binding affinity (>100 fold) without off-target binding and more potent FcRI and FcRII/CD23 inhibition than omalizumab.

August 2023: Inimmune, a biotechnology company based in the United States, has dosed the first patient in a randomised, placebo-controlled Phase I/Ib study of INI-2004 for the treatment of allergic rhinitis. The Toll-Like Receptor 4 (TLR4) agonist product candidate INI-2004 will undergo a single ascending dose study in the first phase of the trial. It will be conducted under the supervision of the Therapeutic Goods Administration Authority and the Human Research Ethics Committee in Australia. The US Food and Drug Administration has also approved Inimmune's investigational new drug application for Phase Ib of the study. This phase will be conducted in the United States and will consist of a multiple ascending dose study with three cohorts. Patients with seasonal allergic rhinitis will be randomly assigned to receive multiple intranasal doses of INI-2004 or placebo in a 3:1 ratio.

List of Electrotherapy Key companies in the market